Thesis
TNX-103's Phase 3 LEVEL readout will determine whether levosimendan can become the first approved therapy for PH-HFpEF
TNX-103 (levosimendan), a calcium sensitizer and phosphodiesterase inhibitor, is in Phase 3 development for pulmonary hypertension complicating heart failure with preserved ejection fraction (PH-HFpEF), a condition with no approved therapies. The thesis turns on whether the LEVEL Phase 3 trial meets its primary endpoint of 25-meter improvement in 6-minute walk distance, with a confirmed power of over 90% following blinded sample size re-estimation. The primary competitive risk is Cytokinetics' CK-586, a cardiac myosin activator targeting overlapping HFpEF patients, alongside the broader sGC stimulator class (riociguat, vericiguat) whose mixed HFpEF track record may inform FDA's evidentiary bar.
Focus
LEVEL Phase 3 topline data readout
Q3 2026
Bull
A positive outcome would require TNX-103 to demonstrate a statistically significant improvement in the primary endpoint of 6-minute walk distance at Week 26, consistent with the ~25m improvement assumed from Phase 2 HELP data. Such a result would position levosimendan as the first approved therapy in PH-HFpEF, a large and currently treatment-orphaned population, and would likely trigger accelerated regulatory engagement, validation of the LEVEL-2 global study, and substantial rerating of the company's commercial prospects.
Bear
The most likely failure modes are a lack of statistically significant improvement in 6MWD — either because the functional benefit does not replicate from Phase 2 to the larger, more heterogeneous Phase 3 population, or because placebo response is higher than anticipated. Secondary endpoints including hemodynamic parameters or hospitalization rates could also fail to support the primary, undermining the regulatory case even if the primary narrowly misses significance.
Unlock the full thesis for TENX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.